Buy & Sell Kimberly Clark Corp (KMB) – Kimberly Clark Corp Price Today
Aura AI Summary
Key Stats
- $32.91BMarket Cap
- Consumer StaplesSector
- -16.5%3M Drawdown
- $39.45BEnterprise Value
- 5.16%Dividend Yield
- 93 daysTypical Hold Time
Kimberly Clark Corp (KMB) is currently valued at a market capitalization of $32.91B, with an enterprise value of $39.45B. Over the past 52 weeks, Kimberly Clark Corp has traded between a low of $93.05 and a high of $143.84, highlighting its annual price range. Over the past three months, Kimberly Clark Corp has recorded a drawdown of -16.5%, reflecting recent price volatility. Kimberly Clark Corp offers a dividend yield of 5.16%, with the most recent dividend of $1.28 paid on 06 Mar 26. On average, investors hold Kimberly Clark Corp for approximately 93 days, indicating typical investor behavior on the platform.
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Most Recent News
Enhanced Games debuts in Las Vegas with boosted athletes and a TikTok-friendly sports format
Enhanced Games will hold its first competition in Las Vegas featuring 50 enhanced athletes, including Olympic and world champions, competing in a new sports format designed for digital and social media viewing. The event combines track, pool, and wei...

Phibro Animal Health CEO sold 21,120 shares worth $1.2 million
Phibro Animal Health's CEO recently sold 21,120 shares of the company, generating proceeds of approximately $1.2 million. This insider sale might indicate the CEO's personal financial planning or a strategic move, but it could also raise questions am...

Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
